Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P656 Clinical implications of endoscopic submucosal dissection in management of patients with ulcerative colitis-associated dysplasia

ECCO'20 Vienna

Year: 2020
Authors:

T. Sakurai1, R. Nezu2, A. Okada3, Y. Komeda1, T. Nagai1, S. Masaki1, M. Yamada1, K. Takashima1, H. Kashida1, M. Kudo1

1Kindai University, Department of Gastroenterology, Osaka-Sayama, Japan, 2Nishinomiya Municipal Central Hospital, Surgery, Nishinomiya, Japan, 3Wakakusa Daiichi Hospital, Gastroenterology, Higashi-Osaka, Japan

P657 Evolution of Crohn’s disease progression and surgery rates over 10 years for patients who initiated biologic treatment early compared with late or no biologic initiation

ECCO'20 Vienna

Year: 2020
Authors:

N. Pillai1, M. Dusheiko1, M. Maillard2, P. Michetti2, V. Pittet PhD1, Swiss IBD Cohort Study

1Center for Primary Care and Public Health - University of Lausanne, Epidemiology and Health Services, Lausanne, Switzerland, 2Gastroenterologie La Source-Beaulieu, Centre Crohn et Colite, Lausanne, Switzerland

P658 A pooled analysis of serum phosphate measurements and transient decreased phosphate levels in 45 interventional trials with ferric carboxymaltose

ECCO'20 Vienna

Year: 2020
Authors:

J.M. Stein1, I. Schiefke2, U.M. Göhring3, V. Fabien4, G. Rosano5

1DGD Hospital Frankfurt-Sachsenhausen, Klinik für Gastroenterologie/Onkologie, Frankfurt/Main, Germany, 2Klinikum St. Georg, Department of Gastroenterology, Hepatology, Diabetology and Endocrinology, Leipzig, Germany, 3Vifor Pharma, Clinical Development, Zurich, Switzerland, 4Vifor Pharma, Biometrics, Zurich, Switzerland, 5St George’s Hospitals NHS Trust, Clinical Academic Cardiovascular Group-, London, UK

P659 The impact of total colectomy on the course of extraintestinal manifestations in Swiss IBD cohort study patients

ECCO'20 Vienna

Year: 2020
Authors:

R. Roth1, S. Vavrick2, M. Scharl1, P. Schreiner1, T. Greuter1, J. Zeitz3, E. Safroneeva4, A. Schoepfer5, M.P. Barry6, G. Rogler1, L. Biedermann1, Swiss IBD Cohort Study

1University Hospital Zurich, Gastroenterology and Hepatology, Zuerich, Switzerland, 2Private Practice, Center for Gastroenterology and Hepatology, Zurich, Switzerland, 3Clinic Hirslanden- Zurich- Switzerland, Center of Gastroenterology, Zurich, Switzerland, 4University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 5Centre Hospitalier Universitaire Vaudois CHUV and University of Lausanne, Division of Gastroenterology and Hepatology, Lausanne, Switzerland, 6Center for Primary Care and Public Health Unisanté – University of Lausanne, Institute of Social and Preventive Medicine IUMSP, Lausanne, Switzerland

P660 Evaluating the effectiveness of disease assessment at 2 weeks following a course of oral steroids: Does early intervention affect outcomes?

ECCO'20 Vienna

Year: 2020
Authors:

J. Slater, A. ALGIEDER, J. Jones, B. Bates, S. De Silva

The Dudley Group NHS Foundation Trust, Gastroenterology, Dudley, UK

P661 Post-operative prophylaxis with anti-TNF in patients with Crohn’s disease who are anti-TNF experienced is associated with higher rates of prophylaxis failure

ECCO'20 Vienna

Year: 2020
Authors:

M. Aharoni Golan1,2, J. Ollech1,2, I. Avni Biron1,2, Y. Broitman1,2, Y. Snir1,2, H. Banai Eran1,2, H. Leibovitzh1,2, I. Goren1,2, N. Wasserberg2,3, I. Dotan1,2, H. Yanai1,2

1Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel, 2Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel, 3Rabin Medical Center, Department of Surgery B, Petah Tikva, Israel

P662 Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: A real-world retrospective study

ECCO'20 Vienna

Year: 2020
Authors:

N. Yoshimura, Soh. Okano, Minako. Sako, Masakazu. Takazoe

Tokyo Yamate Medical Center, Department of Internal Medicine-Division of IBD, Tokyo, Japan

P663 Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies

ECCO'20 Vienna

Year: 2020
Authors:

M. Rutka, K. Farkas, D. Pigniczki, K. Szántó, B. Anita, R. Bor, A. Fábián, Z. Szepes, F. Nagy, T. Molnár

University of Szeged, Department of Medicine I, Szeged, Hungary

P664 The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients: A real-life experience of a single-centre cohort

ECCO'20 Vienna

Year: 2020
Authors:

M. TRUYENS1,2,3, J. Geldof1, G. Dewitte1, E. Glorieus1, G. Varkas2,4, D. Elewaut2,4, T. Lobaton Ortega1,3

1University Hospital Ghent, Gastroenterology, Ghent, Belgium, 2Ghent University, VIB center for Inflammation Research, Ghent, Belgium, 3Ghent University, IBD research unit, Department of Internal Medicine and Pediatrics, Ghent, Belgium, 4Host-Microbiota Interaction Lab and Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent, Belgium

P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study

ECCO'20 Vienna

Year: 2020
Authors:

C. Rayer1, X. Roblin2, D. Laharie3, B. Caron4, M. Flamant5, M. Dewitte1, M. Fumery6, S. Viennot7, A. Bourreille8, B. Pariente9, L. Siproudhis1, L. Peyrin-Biroulet10, G. Bouguen1

1CHU Pontchaillou, Department of Gastroenterology, Rennes, France, 2CHU Saint-Etienne, Gastroenterology, Saint-Etienne, France, 3CHU Bordeaux, Gastroenterology, Bordeaux, France, 4CHU Strasbourg, Department of Gastroenterology, Strasbourg, France, 5Clinique Jules Vernes, Gastroenterology, Nantes, France, 6CHU Amiens, Department of Gastroenterology, Amiens, France, 7CHU Caen, Department of Gastroenterology, Caen, France, 8CHU Nantes, Gastroenterology, Nantes, France, 9CHU Lille, Department of Gastroenterology, Lille, France, 10CHU Nancy, Department of Gastroenterology, Nancy, France

P666 Neutropenia in inflammatory bowel disease patients on TNF inhibitors: A single-centre, retrospective cohort study

ECCO'20 Vienna

Year: 2020
Authors:

D. AlAskar, A. Mais, E. Al Sulais, T. Alameel

King Fahad Specialist Hospital Dammam, Medicine, Dammam, Saudi Arabia

P667 Combined therapy of perianal fistulas with autologous adipose-derived stem cells

ECCO'20 Vienna

Year: 2020
Authors:

A. Surowiecka, M. Łodyga, M. Durlik, R. Grażyna

Central Clinical Hospital of the Ministry of Interior in Warsaw MSWiA, Clinical Department of Gastroenterological Surgery and Transplantation, Warsaw, Poland

P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study

ECCO'20 Vienna

Year: 2020
Authors:

B. Barberio, F. Zingone, R. D’Incà, C. Marinelli, M.C. Maccarone, A. Gubbiotti, L. Cingolani, G. Lorenzon, M. Ghisa, E.V. Savarino

University of Padua, Department of Surgery, Oncology and Gastroenterology, Padua, Italy

P669 Adherence to self-administered biologic therapies in inflammatory bowel disease: Experience in a tertiary hospital

ECCO'20 Vienna

Year: 2020
Authors:

L. Ramos Lopez1, J. Ramos Rodríguez2, R. De La Barreda1, F. Guitierrez2, G.J. Nazco Casariego2, I. Alonso Abreu1, M. Carrillo Palau1, E. Quintero1

1Hospital Universitario De Canarias, Gastroenterology, Santa Cruz De Tenerife, Spain, 2Hospital Universitario De Canarias, Pharmacy, Santa Cruz De Tenerife, Spain

P670 Usefulness of monitoring the concentration of azathioprine metabolites in the children with inflammatory bowel disease and autoimmune hepatitis

ECCO'20 Vienna

Year: 2020
Authors:

K. Bąk-Drabik1, J. Duda-Wrońska2, D. Dąbrowska-Piechota2, P. Adamczyk3

1Department of Peadiatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia- Katowice, Zabrze, Poland, 2Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice Students Association, Department of Peadiatrics, Zabrze, Poland, 3Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Department of Peadiatrics, Katowice, Poland

P671 Natural history and clinical outcomes of patients with ulcerative colitis who are intolerant to 5-aminosalicylic acid agents: A multi-centre cohort study

ECCO'20 Vienna

Year: 2020
Authors:

A. Madarame1, H. Kinoshita1, T. Yamaguchi1, Y. Izumi1, Y. Nishikawa1, S. Shonai1, M. Tatsuno1, Y. Ishii1, K. Yaguchi1, Y. Nakamori1, A. Ikeda1, K. Araki1, A. Hirayama1, T. Ogashiwa1, A. Fuji1, R. Suzuki2, H. Kimura1, R. Kunisaki1

1Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan, 2Kannai Suzuki Clinic, Inflammatory Bowel Disease Centre, Yokohama, Japan

P672 The escalation of therapy or intervention (ETI) calculator for ulcerative colitis: does it have the potential to help outpatient capacity meet demand?

ECCO'20 Vienna

Year: 2020
Authors:

A.J. Walsh, L. Matini, R. Kantschuster, M. Lepetyukh, D. Simadibrata, G. Collins, J. Wilson, M. Hussain, A. Tarafdar, O. Brain, R. Palmer, T. Ambrose, J. Satsangi, S.P.L. Travis

Oxford University Hospitals NHS Foundation Trust and Oxford AHSN, Translational Gastroenterology Unit, Oxford, UK

P673 Strategy of selecting anti-TNF agent in patients with Crohn’s disease: A multi-centre retrospective cohort study by the Osaka gut forum

ECCO'20 Vienna

Year: 2020
Authors:

T. Amano, S. Shinzaki, T. Tashiro, Y. Otake, M. Tani, T. Yoshihara, S. Iwatani, Y. Tsujii, T. Inoue, Y. Hayashi, H. Iijima, T. Takehara, Osaka Gut Forum

Osaka University Graduate School of Medicine, Gastroenterology and Hepatology, Suita, Japan

P674 Monitoring posologic change in adalimumab intensification dosing regimen from 40 mg every week to 80 mg every other week

ECCO'20 Vienna

Year: 2020
Authors:

M.T. Diz Lois Palomares1, Á. Porta Sánchez2, L. Elberdin Pazos2, B. González Conde1, M. Outeda Macías2, M.T. Vázquez Rey1, A. Guerrero Montañés1, E. Estévez Prieto1

1A Coruña Universitary Hospital, Gastroenterology Unit, A Coruña, Spain, 2A Coruña Universitary Hospital, Pharmacy Unit, A Coruña, Spain

P675 CT-Scout platform, the digital solution to boost patient recruitment in inflammatory bowel disease clinical trials: A multicentre prospective observational comparative study

ECCO'20 Vienna

Year: 2020
Authors:

Y. Bouhnik1, X. Hebuterne2, M. Raith3, A. Amiot4, C. Tanasa Stefanescu1, D. Laharie5, X. Roblin6, A. Bourreille7, S. Nancey8, N. Sabbah9, L. Peyrin Biroulet10

1Hopital Beaujon, Service de Gastroentérologie,MICI et Assistance Nutritive, Clichy, France, 2Hopital Archet, Service de Gastroentérologie et Nutrition Clinique, Nice, France, 3CTMA, Project Manajer, Paris, France, 4Hopital Henri Mondor, Service de Gastroentérologie, Creteil, France, 5Hopital Haut-Léveque, Service d’Hépato-Gastroentérologie, Bordeaux, France, 6Hopital Bellevue, Service de Gastroentérologie, Saint Etienne, France, 7CHU Hotel-Dieu, Institut des maladies de l’appareil digestif, Nantes, France, 8Hopital Lyon Sud, Service d’hépatogastroentérologie, Lyon, France, 9CTMA, Chief Operating Officier, Paris, France, 10CHU Nancy, Hépato-Gastro-Entérologie, Nancy, France